Yahoo · Sep 14, 2026
Insider at Medical Device Maker Buys More Than 7,500 Shares
Engert's $150,000 purchase represents a 14% increase to his direct holdings, signaling confidence despite stock's -37% one-year decline.
EN
NYSE · ENOV
Enovis Corporation
Industrials · Industrial - Machinery
$18.04
Up+$0.24 (+1.35%)
Updated Sep 20, 2026, 9:43 PM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
- Market cap
- 1.59B
- P/E ratio
- -1.17
- Dividend yield
- 0.00%
- 52-week range
- $17.30 – $31.67
- Volume
- 2.65M
- Avg. volume
- 806.57K
Price performance
ENOV price history
1M range · 19 trading sessions · Daily adjusted prices
ENOV closed at $18.04 after 19 trading sessions, down 28.44% for the selected period.
- Last close
- $18.04
- Period change
- -28.44%
- Period low
- $17.80
- Period high
- $25.58
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 18, 2026 | $17.70 | $18.09 | $17.47 | $18.04 | 2.65M |
| Sep 17, 2026 | $19.01 | $19.26 | $17.70 | $17.80 | 2.23M |
| Sep 16, 2026 | $18.09 | $18.83 | $17.74 | $18.66 | 1.81M |
| Sep 15, 2026 | $18.07 | $18.59 | $17.30 | $17.94 | 2.66M |
| Sep 14, 2026 | $19.30 | $19.69 | $18.00 | $18.22 | 3.08M |
| Sep 11, 2026 | $18.59 | $19.57 | $18.08 | $19.28 | 2.89M |
| Sep 10, 2026 | $18.70 | $18.89 | $18.23 | $18.41 | 1.76M |
| Sep 9, 2026 | $19.94 | $20.0175 | $18.86 | $19.03 | 1.88M |
| Sep 8, 2026 | $19.15 | $20.215 | $18.57 | $19.98 | 3.74M |
| Sep 4, 2026 | $19.01 | $19.32 | $18.52 | $18.56 | 1.89M |
| Sep 3, 2026 | $20.28 | $20.45 | $19.06 | $19.40 | 2.33M |
| Sep 2, 2026 | $20.50 | $21.06 | $19.72 | $20.20 | 2.48M |
| Sep 1, 2026 | $24.49 | $24.55 | $20.52 | $20.53 | 4.23M |
| Aug 31, 2026 | $24.48 | $24.87 | $23.93 | $24.59 | 672.1K |
| Aug 28, 2026 | $25.20 | $25.38 | $24.79 | $24.90 | 419.87K |
| Aug 27, 2026 | $25.13 | $25.40 | $24.78 | $24.83 | 486.36K |
| Aug 26, 2026 | $25.30 | $25.43 | $24.635 | $25.25 | 553.56K |
| Aug 25, 2026 | $25.23 | $25.65 | $24.68 | $25.58 | 565.37K |
| Aug 24, 2026 | $26.28 | $26.93 | $24.98 | $25.21 | 625.29K |
Latest ENOV news
The latest Smart Investors Daily articles mentioning ENOV.
Stock researchCompany · Overview
ENOV research
Overview
Company profile and research snapshot.
Company profile
Enovis Corp is a medical technology company that offers medical devices and services across the continuum of patient care, from injury prevention to joint replacement to rehabilitation after surgery, injury, or degenerative disease. Its reportable segments are Prevention & Recovery (P&R) and Reconstructive (Recon). The company generates the maximum revenue from the Prevention & Recovery segment, which includes products that are used to treat patients with musculoskeletal conditions resulting from degenerative diseases, deformities, traumatic events, and sports-related injuries. The Reconstructive segment provides a suite of reconstructive joint products for the hip, knee, shoulder, elbow, foot, ankle, and surgical productivity tools. Geographically, it derives key revenue from the U.S.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $64.50
- Implied upside
- —
- Analysts
- 16
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 2, 2026 | Wells Fargo | Overweight | — |
| Sep 2, 2026 | Citizens | Market Outperform | — |
| Sep 2, 2026 | Freedom Capital Markets | Buy | — |
| Sep 2, 2026 | BTIG | Buy | — |
| Sep 1, 2026 | BTIG | Buy | — |
News briefing
No generated briefing is available yet.
Yahoo · Sep 4, 2026
Q2 Earnings Highlights: Enovis (NYSE:ENOV) Vs The Rest Of The Medical Devices & Supplies - Specialty Stocks
As the Q2 earnings season wraps, let’s dig into this quarter’s best and worst performers in the medical devices & supplies - specialty industry, including Enovis (NYSE:ENOV) and its peers.
Yahoo · Sep 4, 2026
Enovis (ENOV) Stock Fair Value Falls As Analysts Weigh Robotics And Margin Pressure
Enovis is back in focus for investors after a modest reset in its implied price target, with fair value in one model shifting from US$42.30 to about US$38.33. Analysts link this move to fresh thinking on the eCential Robotics acquisition, recent free cash flow trends, and the latest Q2 read through to growth plans and execution risk. As you read on, you will see how these moving parts shape the evolving Enovis story and what to watch next in the analyst narrative. Stay updated as the Fair...
Yahoo · Sep 3, 2026
What Makes Enovis (ENOV) a New Buy Stock
Enovis (ENOV) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
AI research layers
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
